Isturisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(2 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(5 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(11 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(12 years from now)

Isturisa is owned by Recordati Rare.

Isturisa contains Osilodrostat Phosphate.

Isturisa has a total of 6 drug patents out of which 0 drug patents have expired.

Isturisa was authorised for market use on 06 March, 2020.

Isturisa is available in tablet;oral dosage forms.

Isturisa can be used as cushing's disease.

Drug patent challenges can be filed against Isturisa from 2024-03-06.

The generics of Isturisa are possible to be released after 12 October, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease


More Information on Dosage

ISTURISA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic